In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chrysalis BioTherapeutics, Inc.

Latest From Chrysalis BioTherapeutics, Inc.

Thoratec's Bleeding Edge

The striking results of the REMATCH trial, demonstrating the efficacy of Thoratec's ventricular assist device to extend the life of terminal heart failure patients, is heartening clinicians and patients and opening up new markets for ventricular assist device manufacturers. Thoratec still faces FDA and reimbursement hurdles before its devices become long-term therapies in large volumes of patients. Meanwhile, the competition hopes to profit from the precedent-breaking REMATCH results, and overtake Thoratec's lead with claims of technological superiority in the long-term heart assist market.

Medical Device Business Strategies

R&R For the Heart

MicroMed Technology has embarked on a strategy aimed at creating a little "R&R" for the failing heart--rest, and revascularization. The company is at the head of a class of start-up companies developing implantable left ventricular devices. But it recently added to its technology platform a drug developed by Chrysalis Biotechnology, that has the potential to revascularize ischemic areas of the heart.

BioPharmaceutical Medical Device
See All

Company Information

  • Other Names / Subsidiaries
    • Chrysalis BioTechnology